Merrimack Pharm (MACK) Posts Narrower than Expected Q2 Loss of 22c/Share
Tweet Send to a Friend
Merrimack Pharm (NASDAQ: MACK) reported Q2 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $12.1 million versus the consensus estimate of $10.9 million.
For earnings history and earnings-related data on Merrimack Pharm (MACK) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Merrimack Pharm (MACK) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Urban Outfitters, Inc. (URBN) Tops Q1 EPS by 3c
- Zoom Technologies, Inc. (ZOOM) Reports Q1 Loss of $0.01
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
